Literature DB >> 26756959

Everolimus-eluting bioresorbable vascular scaffolds versus second generation drug-eluting stents for percutaneous treatment of chronic total coronary occlusions: Technical and procedural outcomes from the GHOST-CTO registry.

Alessio La Manna1, Alberto Chisari1, Giuseppe Giacchi1, Davide Capodanno1, Giovanni Longo1, Michele Di Silvestro1, Piera Capranzano1, Corrado Tamburino1,2.   

Abstract

OBJECTIVES: We aimed at comparing the acute performance of bioresorbable scaffolds (BRS) and second-generation drug-eluting stents (DES) for the treatment of chronic total occlusions (CTO).
BACKGROUND: There is a lack of knowledge regarding the use of BRS in CTO.
METHODS: Key outcomes of interest were technical and procedural success. Technical success was defined as successful stent delivery and implantation, postprocedural residual diameter stenosis <30% within the treated segment, and restoration of thrombolysis in myocardial infarction (TIMI) grade 3 flow. Procedural success was defined as technical success with no in-hospital major adverse cardiac events (MACE).
RESULTS: Between May 2013 and May 2014, 32 patients underwent CTO percutaneous coronary intervention (PCI) with the Absorb BRS (Abbott Vascular, Santa Clara, CA) and were compared with a historical control group of 54 patients who had undergone CTO PCI with second-generation DES. Baseline characteristics were similar between the BRS and DES groups, with the exception of a larger mean reference vessel diameter in the BRS group (2.92 ± 0.34 vs 2.50 ± 0.68; P < 0.001). Technical success was less likely to be achieved in the BRS group compared with the DES group (78.1% vs 96.3%, P = 0.012). Procedural success rates were 78.1% and 94.4% in the BRS and DES group, respectively (P = 0.035).
CONCLUSIONS: Compared with second-generation DES for PCI of CTO lesions, BRS were associated with lower rates of technical and procedural success.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  bioresorbable scaffolds; chronic total occlusions

Mesh:

Substances:

Year:  2016        PMID: 26756959     DOI: 10.1002/ccd.26397

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  4 in total

1.  Optical coherence tomography evaluation of the absorb bioresorbable scaffold performance for overlap versus non-overlap segments in patients with coronary chronic total occlusion: insight from the GHOST-CTO registry.

Authors:  Gabriel T R Pereira; Alessio La Manna; Yasuhiro Ichibori; Armando Vergara-Martel; Bruno Ramos Nascimento; Abdul Jawwad Samdani; Davide Capodanno; Guido D'Agosta; Giacomo Gravina; Giuseppe Venuti; Corrado Tamburino; Guilherme F Attizzani
Journal:  Int J Cardiovasc Imaging       Date:  2019-06-07       Impact factor: 2.357

Review 2.  Approach to CTO Intervention: Overview of Techniques.

Authors:  Aris Karatasakis; Barbara Anna Danek; Dimitri Karmpaliotis; Khaldoon Alaswad; Minh Vo; Mauro Carlino; Mitul P Patel; Stéphane Rinfret; Emmanouil S Brilakis
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-01

3.  Bioresorbable vascular scaffolds for percutaneous treatment of chronic total coronary occlusions: a meta-analysis.

Authors:  Alberto Polimeni; Remzi Anadol; Thomas Münzel; Martin Geyer; Salvatore De Rosa; Ciro Indolfi; Tommaso Gori
Journal:  BMC Cardiovasc Disord       Date:  2019-03-15       Impact factor: 2.298

Review 4.  Bioresorbable vascular scaffolds technology: current use and future developments.

Authors:  Giuseppe Giacchi; Luis Ortega-Paz; Salvatore Brugaletta; Kohki Ishida; Manel Sabaté
Journal:  Med Devices (Auckl)       Date:  2016-07-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.